Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMRAB
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim Animal Health
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
IMRAB is a veterinary rabies vaccine containing inactivated rabies virus, specifically the Pasteur strain (NIH PV-11). Developed and manufactured by Boehringer Ingelheim Animal Health, it is a killed virus biologic designed to provide active immunity against rabies infection in a wide range of animal species, including dogs, cats, horses, cattle, sheep, and ferrets. The vaccine is produced in a stable cell line, chemically inactivated, and typically formulated with an adjuvant such as aluminum hydroxide to enhance the immune response. It is available in several formulations, including IMRAB 1 (annual), IMRAB 3 (three-year), and IMRAB 3 TF (thimerosal-free), catering to different regulatory requirements and species-specific needs.
- Brand names
- IMRABIMRAB 1IMRAB1IMRAB-1IMRAB 3IMRAB3IMRAB-3IMRAB 3 TFIMRAB3 TFIMRAB-3 TFIMRAB Large Animal
- Other names
- Rabies Vaccine, Killed Virus
Beyond the preview
Go deeper on IMRAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMRAB.